Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Gains from Sales and Divestitures (2021 - 2025)

LifeStance Health (LFST) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 9.02% to $6.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 9.02% decrease, with the full-year FY2025 number at $6.6 million, down 9.02% from a year prior.
  • Gains from Sales and Divestitures was $6.6 million for Q4 2025 at LifeStance Health, down from $7.2 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $7.2 million in Q4 2024 to a low of $106.0 in Q4 2021.
  • A 5-year average of $1.5 million and a median of $9103.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 98.22% in 2023, then skyrocketed 149372.16% in 2024.
  • LifeStance Health's Gains from Sales and Divestitures stood at $106.0 in 2021, then soared by 1979.25% to $2204.0 in 2022, then skyrocketed by 119.19% to $4831.0 in 2023, then surged by 149372.16% to $7.2 million in 2024, then dropped by 9.02% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's Gains from Sales and Divestitures are $6.6 million (Q4 2025), $7.2 million (Q4 2024), and $7.1 million (Q3 2024).